Brief: Arch Biopartners to manufacture drug AB569 with Catalent Inhalation
10/08/2016 12:47
Aug 10 (Reuters) - Arch Biopartners Inc ACH.V :
* Engaged Catalent Inhalation, a division of Catalent Pharma
Solutions, to begin manufacturing process for drug ab569
* Catalent Inhalation to undertake initial stability and
formulation studies, later manufacture a supply of ab569
* Engaged Catalent Inhalation in preparation for first human
trials involving patients with antibiotic resistant lung
infections
Source text for Eikon: ID:nMKWMfdXpa
Further company coverage: ACH.V
((Bengaluru Newsroom - +1 646 223 8780;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide